Results 101 to 110 of about 53,515 (238)
In this study including 31 circumscribed meningeal melanocytic neoplasms (melanocytoma, intermediate‐grade melanocytic tumor [IMT], and melanoma), overall survival (OS) differed significantly among the groups, with melanoma showing significantly worse OS than melanocytoma and IMT showing intermediate OS between melanocytoma and melanoma.
Yi Zhu +12 more
wiley +1 more source
Myasthenia Gravis Induced by Ipilimumab in a Patient With Metastatic Melanoma
In daily clinical practice, there is a growing number of patients receiving new biological agents used in the treatment of malignancies. Ipilimumab is a fully humanized monoclonal antibody approved for patients with melanoma.
Vera Montes +4 more
doaj +1 more source
Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu +6 more
wiley +1 more source
Immune checkpoint inhibitors, such as ipilimumab and nivolumab, reverse the imbalance of antitumor self-tolerance and enhance T-cell responses. Currently, ipilimumab and nivolumab have a reported therapeutic impact on unresectable or metastatic melanomas;
Akira Utsunomiya +6 more
doaj +1 more source
Real-world impact of education: treating patients with ipilimumab in a community practice setting
Blanca Ledezma,1 Annie Heng2 1Department of Hematology and Oncology, University of California, Los Angeles, Santa Monica, CA, USA; 2Angeles Clinic and Research Institute, Los Angeles, CA, USA Abstract: After decades without promising new treatments for ...
Heng A, Ledezma B
core
Overall survival of patients treated with ipilimumab grouped by (A) BMI and (B) LDH levels. Progression-free survival rates of patients treated with ipilimumab, grouped by BMI (C).
Rainer Huegel (5807369) +16 more
core +1 more source
Abstract Background and Purpose Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy, offering improvements in survival across various malignancies. However, their toxicities pose a major challenge for cardio‐oncology units. Despite their growing importance, data on effectiveness of such specialized units in mitigating ICI‐associated ...
Elias Haj‐Yehia +6 more
wiley +1 more source
Cardiovascular toxicity from immune checkpoint inhibitor therapy: an inflammatory continuum
Immune checkpoint inhibitor (ICI) therapy has markedly improved outcomes in advanced malignancies but has also revealed a distinct spectrum of cardiovascular immune‐related adverse events. Myocarditis represents the most severe manifestation, while non‐inflammatory left ventricular dysfunction and vascular inflammation have emerged as additional ...
Fabrice Reyes +7 more
wiley +1 more source
Immune checkpoint inhibitor (ICI)‐associated myocarditis has emerged as a severe and clinically complex immune‐related toxicity that poses significant challenges for therapeutic decision‐making in routine cardio‐oncological care. High‐dose corticosteroids remain the first‐line therapy, yet their timing, dosage and tapering require careful clinical ...
Raluca I. Mincu +10 more
wiley +1 more source

